Global Erosive Hand Osteoarthritis Market is Segmented By Treatment (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)(Ibuprofen, Naproxen, Diclofenac, High-Dose Aspirin and Others), Analgesics, Steroid Injections, Heat Therapy, Occupational Therapy, Disease-Modifying Antirheumatic Drugs and Biologics (DMARDS), Others), By End-User(Hospitals, Specialty Clinics, Research and Academic Centers and Others)
Market Overview
Global Erosive Hand Osteoarthritis Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
The global erosive hand osteoarthritis market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics such as increasing prevalence, rising clinical trials, and others. Government investments in better treatment will continue to drive and boost the global market. The erosive hand osteoarthritis is also known as inflammatory osteoarthritis characterized by affecting the interphalangeal joints of the hand.
The erosive hand osteoarthritis is a rare type of osteoarthritis condition and the treatment is based on the severity of the condition. Currently, there is no cure for this disease, but the treatment includes managing the symptoms and severity by using NSAIDs, analgesics, heat therapy, occupational therapy, steroid or corticosteroid injections, disease-modifying antirheumatic drugs and biologics (DMARDS), and others.
The NSAIDs segment holds the largest market share and it is considered a first-line treatment. Similarly, North America dominates the erosive hand osteoarthritis market, capturing the largest market share owing to the region’s advanced healthcare infrastructure, and presence of major players.
Moreover, owing to the increasing prevalence of erosive osteoarthritis, growing awareness, rising clinical trials, increasing demand for novel therapeutics, and advancements in treatment options are the major factors expected to drive the global erosive hand osteoarthritis market over the forecast period.
Market Scope
|
Metrics |
Details |
|
CAGR |
XX% |
|
Size Available for Years |
2021-2030 |
|
Forecast Period |
2023-2030 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Treatment, End-User |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
Market Dynamics
Increasing Demand for Novel Therapeutics is Expected to Drive the Growth of the Market
There is an increasing demand for novel therapeutics, which is expected to drive the global market over the forecast period. The currently available treatments and therapeutics are not effective for all patients, and there is also a need for new therapies and therapeutics that can achieve better and enhanced treatment results. Novel therapeutics aim to address the unmet needs associated with erosive hand osteoarthritis by providing alternative or complementary treatment options to manage the condition in better ways.
For instance, on February 05, 2023, according to the University of Oxford, erosive hand osteoarthritis is a widespread and crippling ailment that disproportionately affects women, particularly during menopause. The research team began by studying a prevalent gene variant associated with severe hand osteoarthritis (OA). By analyzing patient samples collected during routine hand surgery and conducting various experimental models, they discovered a crucial molecule, talarozole which increases the retinoic acid, that was deficient in individuals at high risk for the condition.
Moreover, the ongoing research activities on erosive hand osteoarthritis enhance the treatment opportunities with better patient outcomes, and the development of innovative treatment approaches have led to the discovery of potential novel therapeutic options such as topical agents, oral agents, and better medical devices for enhanced treatment and diagnosis. These advancements increase the way for the introduction of novel drugs and devices with different mechanisms of action.
Further, erosive hand osteoarthritis can be a painful and debilitating condition, and traditional treatments may not provide adequate relief for all patients. This unmet medical need creates a demand for more effective and targeted therapies. Advances in medical imaging and diagnostic techniques have led to better and earlier diagnosis. With more individuals being diagnosed, there is a greater demand for therapies that can address the condition's specific symptoms.
Rising Clinical Trials is Also Expected to Drive the Growth of the Market
The rising clinical trials are expected to drive the growth of the market over the forecast period. Clinical trials provide a platform for testing new and innovative therapies specifically designed for erosive hand osteoarthritis. These trials may include novel medications, biologics, medical devices, or regenerative therapies that have the potential to be more effective and expected to have fewer side effects than existing treatments.
For instance, on December 13, 2022, the University of Ghent in Belgium, announced the clinical trial results for erosive hand osteoarthritis. The structure-modifying effect of subcutaneous denosumab was evaluated in patients with erosive hand osteoarthritis to explore the clinical benefits and safety of the drug compared with placebo. Results of the study indicated that the drug had significant structure-modifying effects in this patient population, with significantly less erosive progression and symptom improvement after 24 weeks of treatment, with further enhancements reported at 48 weeks.
Furthermore, clinical trials build trust in patients about the safety and efficacy of the therapeutics. The positive results from clinical trials can boost investor confidence and patient trust in the usage of medicines for treatment. This increased confidence can attract funding for further research and development and conduct more clinical trials, allowing companies to invest in more innovative therapeutics and driving the market.
For instance, on April 04, 2023, Diakonhjemmet Hospital in collaboration with Oslo University Hospital stated the updates on the clinical trials for methotrexate in erosive inflammatory hand osteoarthritis. The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis. The study is estimated to be completed on October 30, 2024.
Complications Associated with the Use of NSAIDs is Expected to Hamper the Market's Growth
The risks associated with the usage of NSAIDs are expected to hamper the market growth over the forecast period. NSAIDs are considered as first-line treatment for the treatment of erosive hand osteoarthritis, and also they are known to increase the risk of gastrointestinal complications, such as ulcers, bleeding, and gastritis. Patients with erosive hand osteoarthritis who require long-term NSAID use may be at higher risk for these complications. This may leads to seeking alternative treatment options.
Furthermore, Certain NSAIDs are also associated with an increased risk of cardiovascular complications, such as heart attacks and strokes. And they can also have certain kidney function effects due to their long-term and high-dose usage. This caution can influence treatment choices and potentially limit the use of NSAIDs.
Segment Analysis
The global erosive hand osteoarthritis market is segmented based on treatment, end-user, and region.
The NSAIDs Segment Accounted for Approximately 47.4% of the Erosive Hand Osteoarthritis Market Share
NSAIDs segment holds the largest market share over the forecast period. They are considered as first-line treatment for the treatment of erosive hand osteoarthritis. NSAIDs including ibuprofen, naproxen, diclofenac, high-dose aspirin, and others are primarily used to relieve pain and reduce inflammation. The erosive hand osteoarthritis patients experience significant pain and inflammation in their affected joints, so NSAIDs may be considered as a treatment option.
Moreover, the severity of erosive hand osteoarthritis can vary from person to person. NSAIDs are prescribed based on the severity of the condition and may be more commonly prescribed when the symptoms are moderate to severe and impact daily functioning. Basically, prior treatments, such as topical therapies or physical therapy, can be attempted. If these interventions do not provide sufficient relief, NSAIDs may be recommended.
Geographical Penetration
North America Accounted for Approximately 39.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare infrastructure. North America is commonly known for its strong presence of major players such as many pharmaceutical and medical device companies. This strong presence of major players increases the clinical trials and research activities for the treatment of erosive hand osteoarthritis.
For instance, on January 31, 2023, Amgen announced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), is now available in the United States. AMJEVITA is the first U.S. biosimilar to Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases including inflammatory osteoarthritis. Amgen is uniquely equipped to supply this biosimilar medicine while reducing costs.
Additionally, North America, especially in the United States and Canada is also well-known for its advanced healthcare infrastructure such as hospitals, specialty clinics, academic and research centers, and others. This advanced and well-established healthcare infrastructure helps to manage the symptoms and severity of the condition by offering better treatment in a better manner, this further leads to market dominance in the region.
Competitive Landscape
The major global players in the erosive hand osteoarthritis market include Sanofi, Zimmer Biomet, Horizon Therapeutics plc, GSK plc., Novartis AG, Bayer AG, Elam Pharma Pvt. Ltd., LEXICARE PHARMA PVT. LTD., Stryker, and Anika Therapeutics, Inc., among others.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global erosive hand osteoarthritis market. During the pandemic, many clinical trials, research activities, and regulatory approvals have been temporarily postponed due to the redirected focus on COVID-19 treatment and management and its related restrictions.
The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide. Many hospitals are focused on COVID-19 cases, this reduced the treatment and management of erosive or inflammatory hand osteoarthritis.
Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as therapeutics and medical devices. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks. The COVID-19 vaccination increased the severity of erosive osteoarthritis in many patients.
Key Developments
- On August 17, 2023, the University of Reading, announced that they will develop inflammatory arthritis (IA) using artificial intelligence (AI) as the goal of a research project. Professor Weizi Li was awarded £600,000 to investigate how machines can be developed to better detect the onset of IA, a disease that affects around 10 million people in the UK according to the NHS. Funded by UK Research and Innovation (UKRI), it is hoped the project will eventually ease pressure on the NHS by helping doctors to achieve earlier IA diagnoses.
DataM Intelligence Opinion:
According to the DataM Intelligence, the erosive hand osteoarthritis market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and rising clinical trials for safety and better patient outcomes. However, there are many risks associated with the usage of NSAIDs, which is expected to hamper the market growth.
Moreover, many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global market in the upcoming years.
Why Purchase the Report?
- To visualize the global erosive hand osteoarthritis market segmentation based on treatment, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of erosive hand osteoarthritis market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global erosive hand osteoarthritis market report would provide approximately 61 tables, 58 figures, and 186 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Suggestions for Related Report
For more Pharmaceutical related reports, please click here
